Market Overview

Leerink Highlights Biotechs Poised To Benefit From ASH Conference

Share:
Leerink Highlights Biotechs Poised To Benefit From ASH Conference
Related ALNY
20 Stocks Moving In Wednesday's Pre-Market Session
20 Biggest Mid-Day Gainers For Monday
Related JUNO
Gilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug
22 Stocks Moving In Thursday's Pre-Market Session
These 5 Top Stocks Are Moving Late On News: S&P 500 Futures (Investor's Business Daily)

  • On Monday, Leerink issued a report previewing the American Society of Hematology annual meeting, which will be held from December 5 to December 8.
  • Leerink believes that this meeting will have meaningful clinical updates for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Juno Therapeutics Inc (NASDAQ: JUNO) and Karyopharm Therapeutics Inc (NASDAQ: KPTI).
  • Leerink reiterated their OP rating for all three issues.
  • Michael Schmidt and Jonathan Chang, analysts at Leerink, highlighted Juno, Karyopharm and Alnylam in their report ahead of the annual ASH Conference.

    Alnylam

    "ALNY will present important updates from ALN-CC5 (complement-mediated diseases) and ALN-AT3 (bleeding disorders) Phase I trials, respectively, including multi-dose cohorts, which should further validate early clinical results presented from either agent this summer."

    Related Link: La Jolla Pharmaceutical Company Announces Notice Of Allowance For U.S. Patent Covering

    Juno

    "Six ASH presentations for JUNO will include updates from JCAR014 (anti-CD19, FHCRC) trials in NHL, chronic lymphocytic leukemia (CLL)... We'd expect updates at ASH to include more pts and data on durability in NHL, which could help position JUNO's product vs. competitors."

    Karyopharm

    "Clinical data presentations on selinexor combinations include (1) a summary of Ph II dose finding trials showing that a flat dose of 60mg selinexor twice weekly provides the best risk-benefit profile."

    Overall, the analysts believe that this presentation will contain meaningful data that could serve as catalysts for these companies going forward, particularly as it relates to Phase 1 and Phase 2 data. Positive data may validate early clinical results leading to positive investor sentiment.

    Alnylam Pharmaceuticals shares recently traded at $105.37, down 1.87 percent on Monday.

    Juno Therapeutics recently traded at $55.83, down 0.89 percent on Monday.

    Karyopharm Therapeutics shares recently traded at $18.38, down 3.16 percent on Monday.

    Image Credit: Public Domain

    Latest Ratings for ALNY

    DateFirmActionFromTo
    Oct 2017Goldman SachsUpgradesNeutralBuy
    Sep 2017BMO CapitalMaintainsOutperform
    Sep 2017BarclaysMaintainsOverweight

    View More Analyst Ratings for ALNY
    View the Latest Analyst Ratings

    Posted-In: Analyst Color Biotech Long Ideas Health Care Reiteration Top Stories Analyst Ratings Trading Ideas Best of Benzinga

     

    Related Articles (ALNY + JUNO)

    View Comments and Join the Discussion!
    Loading...

    Partner Center

    Loading...